Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 Early data in 2026 shows an...
Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, continues its investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX ...
The Law Offices of Frank R. Cruz continues its investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX ) on behalf of investors concerning the Company’s possible...
Law Offices of Howard G. Smith continues its investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX ) investors concerning the Company’s possible violations...
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients...
NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact...
NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact...
Law Offices of Howard G. Smith announces an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX ) investors concerning the Company’s possible violations...
The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX ) on behalf of investors concerning the Company’s possible...
Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”)...